INmune Bio (NASDAQ:INMB) Announces Earnings Results

INmune Bio (NASDAQ:INMB) issued its quarterly earnings results on Thursday. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02), FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• Positive sentiment: INmune Bio expects to submit its U.K. marketing authorization application for Ebstrocel in early February 2027, with potential approval around mid-2027. The company also targets a U.S. BLA submission in mid-2027, subject to FDA feedback.
• Positive sentiment: The MHRA has provided written alignment on planned clinical, non-clinical, and manufacturing elements, and the company says manufacturing and quality controls are being prepared for reliable supply. These steps support its application, but do not guarantee approval.
• Positive sentiment: A Uniphar agreement could enable named-patient access in eligible international markets before local approvals and create an earlier revenue opportunity. INmune cautioned that timing and scale depend on country-level arrangements, physician requests, and funding or reimbursement; no sales forecast was provided.
• Negative sentiment: INmune reported $16.3 million in cash at quarter-end and raised $4.5 million gross through an October stock-and-warrant offering, with cash expected to fund operations through Q3 2027. The company’s reduced quarterly loss and expenses were partly offset by the limited runway and potential share dilution.

INmune Bio Stock Down 3.8%

Shares of NASDAQ:INMB opened at $1.13 on Friday. The stock has a market capitalization of $31.59 million, a PE ratio of -1.88 and a beta of 0.97. INmune Bio has a twelve month low of $1.06 and a twelve month high of $2.60. The firm’s 50 day moving average price is $1.88 and its 200-day moving average price is $1.63.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Wall Street Zen cut INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings raised INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company focused on developing treatments that harness and modulate the innate immune system. The company’s research is aimed at addressing diseases in which chronic inflammation or impaired immune function plays a significant role, including cancer, neurodegenerative disorders and certain psychiatric conditions.

Its lead product candidate is XPro, a next-generation tumor necrosis factor inhibitor designed to selectively neutralize soluble TNF while preserving transmembrane TNF signaling.